Albion Financial Group UT Acquires 248 Shares of AstraZeneca PLC (NASDAQ:AZN)

Albion Financial Group UT increased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 68.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 608 shares of the company’s stock after buying an additional 248 shares during the quarter. Albion Financial Group UT’s holdings in AstraZeneca were worth $40,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Bank of Montreal Can increased its holdings in shares of AstraZeneca by 109.6% during the third quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock worth $238,397,000 after buying an additional 1,605,758 shares in the last quarter. Franklin Resources Inc. increased its holdings in AstraZeneca by 8.7% in the 3rd quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock worth $1,492,649,000 after purchasing an additional 1,522,715 shares in the last quarter. Erste Asset Management GmbH bought a new position in AstraZeneca in the third quarter valued at about $72,437,000. Fisher Asset Management LLC grew its holdings in shares of AstraZeneca by 5.3% during the third quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock worth $816,509,000 after purchasing an additional 524,175 shares during the last quarter. Finally, AXA S.A. increased its stake in shares of AstraZeneca by 1,039.6% in the second quarter. AXA S.A. now owns 400,242 shares of the company’s stock valued at $31,215,000 after buying an additional 365,121 shares during the period. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on AZN. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Trading Up 0.4 %

NASDAQ:AZN opened at $68.20 on Thursday. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The firm’s fifty day moving average is $66.20 and its 200-day moving average is $74.32. The firm has a market cap of $211.49 billion, a P/E ratio of 32.63, a P/E/G ratio of 1.13 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the prior year, the firm posted $0.87 earnings per share. The business’s quarterly revenue was up 18.0% compared to the same quarter last year. Equities analysts expect that AstraZeneca PLC will post 4.12 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.